The very favorable results from treatment of Type I pneumonias and the encouraging although less favorable results in Type II led the clinicians who were aiding in the general pneumonia investigation* to try serum treatment in Type III infections. As the observations and statistics of Bullowa, t Rosenbluth) Park, Bullowa and Rosenbluth, ~ Cecil and Sutliff s of the treatment of patients with Type III pneumonia with specific antiserum did not indicate very favorable results, it seemed to us that it would be interesting to study the effect of the Type III antiserum in the treatment of pneumonia in experimental animals. The progress of the disease could be compared with that of Type I pneumonia in which serum treatment of patients has proved to be of value. In case the animals could be infected and cured, the relative amount of serum necessary could be found and might furnish data on which to base a plan of dosage for further clinical trial of the antiserum.The production of an infection by intradermal inoculation and the subsequent intravenous inoculation of a single dose of antiserum was carried out by a technique slightly modified from that used by Good-
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.